Nuclear factor Y regulation and promoter transactivation of human ribonucleotide reductase subunit M2 gene in a Gemcitabine resistant KB clone

Biochemical Pharmacology

Volumn 67, Issue 8, 2004, Pages 1499-1511

  Liu, Xiyong ^a   Zhou, Bingsen ^a   Xue, Lijun ^a   Qiu, Weihua ^a   Shih, Jennifer ^a   Zheng, Shu ^b   Yen, Yun ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

hRR; hRRM1; hRRM2; Human ribonucleotide reductase; Human ribonucleotide reductase subunit M1; Human ribonucleotide reductase subunit M2; KBGem; NF Y; Nuclear factor Y; p53 dependant ribonucleotide reductase subunit R2; p53R2

Indexed keywords

ANTIBODY; GEMCITABINE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; LUCIFERASE; NUCLEAR FACTOR; NUCLEAR FACTOR Y; PROTEIN SUBUNIT; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ARTICLE; ASSAY; BINDING AFFINITY; CELL CLONE; CELL PROLIFERATION; CELL STRAIN KB; CONTROLLED STUDY; DNA MICROARRAY; DNA PROTEIN COMPLEX; ENZYME ACTIVITY; ENZYME ASSAY; GENE; GENE EXPRESSION; GENE OVEREXPRESSION; GENE REPRESSION; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN RIBONUCLEOTIDE REDUCTASE M2 GENE; MOLECULAR CLONING; MOLECULAR RECOGNITION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA BINDING; REGULATORY MECHANISM; SOUTHWESTERN BLOTTING; TRANSACTIVATION; TRANSCRIPTION REGULATION; UNINDEXED SEQUENCE; UPREGULATION;

ANTIMETABOLITES, ANTINEOPLASTIC; BIOLOGICAL TRANSPORT; CCAAT-BINDING FACTOR; CCAAT-ENHANCER-BINDING PROTEINS; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; HUMANS; HYDROXAMIC ACIDS; KB CELLS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS (GENETICS); RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS;

EID: 1642407593     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2003.12.026     Document Type: Article

References (39)

1. Jordan A., Reichard P. Ribonucleotide reductases. Annu. Rev. Biochem. 67:1998;71-98.
2. Rova U., Adrait A., Pötsch S., Gräslund A., Thelander L. Evidence by mutagenesis that Tyr (370) of the mouse ribonucleotide reductase R2 protein is the connecting link in the intersubunit radical transfer pathway. J. Biol. Chem. 274:1999;23746-23751.
3. Tanaka H., Arakawa H., Yamaguchi T., Shiraishi K., Fukuda S., Matsui K., Takei Y., Nakamura Y. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature. 404:2000;42-49.
4. Nakano K., Balint E., Ashcroft M., Vousden K.H. A ribonucleotide reductase gene is a transcriptional target of p53 and p73. Oncogene. 19:2000;4283-4289.
5. Yamaguchi T., Matsuda K., Sagiya Y., Iwadate M., Fujino M.A., Nakamura Y., Arakawa H. p53R2-dependent pathway for DNA synthesis in a p53-regulated cell cycle checkpoint. Cancer Res. 61:2001;8256-8262.
6. Guittet O., Häkansson P., Voevodskaya N., Gräslund A., Arakawa H., Nakamura Y., Thelander L. Mammalian p53R2 protein forms an active ribonucleotide reductase in vitro with the R1 protein, which is expressed both in resting cells in response to DNA damage and in proliferating cells. J. Biol. Chem. 276:2001;40647-40651.
7. Galmarini C.M., Mackey J.R., Dumontet C. Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia. 15:2001;875-890.
8. Mackey J.R., Jennings L.L., Clarke M.L., Santos C.L., Dabbagh L., Vsianska M., Koski S.L., Coupland R.W., Baldwin S.A., Young J.D., Cass C.E. Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers. Clin. Cancer Res. 8:2002;110-116.
9. Plunkett W., Huang P., Xu Y.Z., Heinemann V., Grunewald R., Gandhi V. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin. Oncol. 22:1995;3-10.
10. Heinemann V., Hertel L.W., Grindey G.B., Plunkett W. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′- difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res. 48:1988;4024-4031.
11. Hunsucker S.A., Spychala J., Mitchell B.S. Human cytosolic 5'-nucleotidase I: characterization and role in nucleoside analog resistance. J. Biol. Chem. 276:2001;10498-10504.
12. Heinemann V., Xu Y.Z., Chubb S., Sen A., Hertel L.W., Grindey G.B., Plunkett W. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol. Pharmacol. 38:1990;567-572.
13. Gourdeau H., Clarke M.L., Ouellet F., Mowles D., Selner M., Richard A., Lee N., Mackey J.R., Young J.D., Jolivet J., Lafrenière R.G., Cass C.E. Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines. Cancer Res. 61:2001;7217-7224.
14. Ruiz van Haperen V.W., Veerman G., Eriksson S., Boven E., Stegmann A.P., Hermsen M., Vermorken J.B., Pinedo H.M., Peters G.J. Development and molecular characterization of a 2,2-difluorodeoxycytidine resistant variant of the human ovarian carcinoma cell line A2780. Cancer Res. 54:1994;4138-4143.
15. Goan Y.G., Zhou B.S., Hu E., Mi S., Yen Y. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2- difluorodeoxycitidine in the human KB cancer cell line. Cancer Res. 59:1999;4204-4207.
16. Zhou B.S., Mo X.L., Liu X.Y., Qiu W.H., Yen Y. Human ribonucleotide Reductase M2 subunit gene amplification and transcriptional regulation in a homogeneous staining chromosome region responsible for the mechanism of drug resistance. Cytogenet. Cell Genet. 95:2001;34-42.
17. Zhou B.S., Yen Y. Characterization of the human ribonucleotide reductase M2 subunit gene Genomic structure and promoter analyses. Cytogenet. Cell Genet. 95:2001;52-59.
18. Park J.B., Levine M. Characterization of promoter of the human ribonucleotide reductase R2 gene. Biochem. Biophys. Res. Commun. 267:2000;651-657.
19. Maity S.N., de Crombrugghe B. Role of the CCAAT-binding protein CBF/NF-Y in transcription. Trends Biochem. Sci. 23:1998;174-178.
20. Kim I.S., Sinha S., de Crombrugghe B., Maity S.N. Determination of functional domains in the C subunit of the CCAAT-binding factor (CBF) necessary for formation of a CBF-DNA complex: CBF-B interacts simultaneously with both the CBF-A and CBF-C subunits to form a heterotrimeric CBF molecule. Mol. Cell Biol. 16:1996;4003-4013.
21. Jin S., Scotto K.W. Transcriptional regulation of MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y. Mol. Cell Biol. 18:1998;4377-4384.
22. Xue L., Zhou B., Liu X., Qiu W., Jin Z., Yen Y. Wild-type p53 regulates human ribonucleotide reductase by protein-protein interaction with p53R2 as well as hRRM2 subunits. Cancer Res. 63:2003;980-986.
23. Zhou B.S., Ker R., Ho R., Yu J., Zhao Y.R., Shih J., Yen Y. Determination of deoxyribonucleoside triphosphate pool sizes in ribonucleotide reductase cDNA transfected human KB cells. Biochem. Pharmacol. 55:1998;1657-1665.
24. Qiu W., David D., Zhou B., Chu P.G., Zhang B., Wu M., Xiao J., Han T., Zhu Z., Wang T., Liu X., Lopez R., Frankel P., Jong A., Yen Y. Down-regulation of growth arrest DNA damage-inducible gene 45β expression is associated with human hepatocellular carcinoma. Am. J. Pathol. 162:2003;1961-1974.
25. Lum L.S., Sultzman L.A., Kaufman R.J., Linzer D.I., Wu B.J. A cloned human CCAAT-box-binding factor stimulates transcription from the human hsp70 promoter. Mol. Cell Biol. 10:1990;6709-6717.
26. Zhou B., Mi S., Mo X., Shih J., Tsai J., Hu E., Hsu M., Kay K., Yen Y. Time and sequence dependence of hydroxyurea in combination with Gemcitabine in human KB cells. Anticancer Res. 22:2002;1369-1377.
27. Manni I., Mazzaro G., Gurtner A., Matovani R., Haugwitz U., Krause K., England K., Sacchi A., Soddu S., Piaggio G. NF-Y mediates the transcriptional inhibition of the cyclin B1, cyclin B2, and cdc25C promoter upon induced G2 arrest. J. Biol. Chem. 276:2001;5570-5576.
28. Jung C.P., Motwani M.V., Schwartz G.K. Flavopiridol increases sensitization to Gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit. Clin. Cancer Res. 17:2000;2527-2536.
29. Wong S.J., Myette M.S., Wereley J.P., Chitambar C.R. Increased sensitivity of hydroxyurea-resistant leukemic cells to Gemcitabine. Clin. Cancer Res. 5:1999;439-443.
30. Yen Y., Grill S.P., Dutschman G.E., Chang C.N., Zhou B.S., Cheng Y.C. Characterization of a hydroxyurea-resistant human KB cell line with supersensitivity to 6-thioguanine. Cancer Res. 54:1994;3686-3691.
31. Zhou B.S., Hsu N.Y., Pan B.C., Doroshow J.H., Yen Y. Overexpression of ribonucleotide reductase in transfected human KB cells increases their resistance to hydroxyurea: M2 but not M1 is sufficient to increase resistance to hydroxyurea in transfected cells. Cancer Res. 55:1995;1328-1333.
32. Mantovani R. A survey of 178 NF-Y binding CCAAT boxes. Nucleic Acids Res. 26:1998;1135-1143.
33. Currie R.A. NF-Y is associated with the histone acetyltransferases GCN5 and P/CAF. J. Biol. Chem. 273:1998;1430-1434.
34. Huang A., Fan H., Taylor W.R., Wright J.A. Ribonucleotide reductase R2 gene expression and changes in drug sensitivity and genome stability. Cancer Res. 57:1997;4876-4881.
35. Zhou B.S., Tsai P., Ker R., Tsai J., Ho R., Yu J., Shih J., Yen Y. Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential. Clin. Exp. Metastasis. 16:1998;43-49.
36. Amara F.M., Chen F.Y., Wright J.A. A novel transforming growth factor-β 1 responsive cytoplasmic trans-acting factor binds selectively to the 3′-untranslated region of mammalian ribonucleotide reductase R2 mRNA: role in message stability. Nucleic Acids Res. 21:1993;4803-4809.
37. Burton T.R., Kashour T., Wright J.A., Amara F.M. Cellular signaling pathways affect the function of ribonucleotide reductase mRNA binding proteins: mRNA stabilization, drug resistance, and malignancy (Review). Int. J. Oncol. 22(1):2003;21-31.
38. Park S.H., Lee S.R., Kim B.C., Cho E.A., Patel S.P., Kang H.B., Sausville E.A., Nakanishi O., Trepel J.B., Lee B.I., Kim S.J. Transcriptional regulation of the transforming growth factor β type II receptor gene by histone acetyltransferase and deacetylase is mediated by NF-Y in human breast cancer cells. J. Biol. Chem. 277:2002;5168-5174.
39. Caretti G., Salsi V., Vecchi C., Imbriano C., Mantovani R. Dynamic recruitment of NF-Y and histone acetyltransferases on cell-cycle promoters. J. Biol. Chem. 278:2003;30435-30440.